Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.

Hameed B, Terrault NA, Gill RM, Loomba R, Chalasani N, Hoofnagle JH, Van Natta ML; NASH CRN.

Aliment Pharmacol Ther. 2018 Mar;47(5):645-656. doi: 10.1111/apt.14492. Epub 2018 Jan 14.

PMID:
29333665
2.

Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children.

Newton KP, Feldman HS, Chambers CD, Wilson L, Behling C, Clark JM, Molleston JP, Chalasani N, Sanyal AJ, Fishbein MH, Lavine JE, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).

J Pediatr. 2017 Aug;187:141-146.e1. doi: 10.1016/j.jpeds.2017.03.007. Epub 2017 Mar 30.

PMID:
28366357
3.

In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis.

Africa JA, Behling CA, Brunt EM, Zhang N, Luo Y, Wells A, Hou J, Belt PH, Kohil R, Lavine JE, Molleston JP, Newton KP, Whitington PF, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network.

Clin Gastroenterol Hepatol. 2018 Mar;16(3):438-446.e1. doi: 10.1016/j.cgh.2017.02.030. Epub 2017 Mar 7.

PMID:
28286193
4.

In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.

Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, Barlow SE, Vos MB, Karpen SJ, Molleston JP, Whitington PF, Rosenthal P, Jain AK, Murray KF, Brunt EM, Kleiner DE, Van Natta ML, Clark JM, Tonascia J, Doo E; NASH CRN.

Gastroenterology. 2016 Dec;151(6):1141-1154.e9. doi: 10.1053/j.gastro.2016.08.027. Epub 2016 Aug 26.

5.

Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.

Nelson JE, Handa P, Aouizerat B, Wilson L, Vemulakonda LA, Yeh MM, Kowdley KV; NASH Clinical Research Network.

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1253-1264. doi: 10.1111/apt.13824. Epub 2016 Oct 11.

6.

Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.

Yang JD, Abdelmalek MF, Guy CD, Gill RM, Lavine JE, Yates K, Klair J, Terrault NA, Clark JM, Unalp-Arida A, Diehl AM, Suzuki A; Nonalcoholic Steatohepatitis Clinical Research Network.

Clin Gastroenterol Hepatol. 2017 Jan;15(1):127-131.e2. doi: 10.1016/j.cgh.2016.07.034. Epub 2016 Aug 12.

7.

Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease.

Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network.

J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):360-7. doi: 10.1097/MPG.0000000000000584.

8.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network.

Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7. Erratum in: Lancet. 2015 Mar 14;385(9972):946. Lancet. 2016 Apr 16;387(10028):1618.

9.

NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.

Corey KE, Vuppalanchi R, Wilson LA, Cummings OW, Chalasani N; NASH CRN.

Aliment Pharmacol Ther. 2015 Feb;41(3):301-9. doi: 10.1111/apt.13035. Epub 2014 Nov 28.

10.

Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease.

Schwimmer JB, Zepeda A, Newton KP, Xanthakos SA, Behling C, Hallinan EK, Donithan M, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network.

PLoS One. 2014 Nov 24;9(11):e112569. doi: 10.1371/journal.pone.0112569. eCollection 2014.

11.

Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels.

Molleston JP, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, Brunt EM, Scheimann AO, Unalp-Arida A; NASH Clinical Research Network.

J Pediatr. 2014 Apr;164(4):707-713.e3. doi: 10.1016/j.jpeds.2013.10.071. Epub 2013 Dec 19.

12.

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.

Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN).

Aliment Pharmacol Ther. 2013 Jul;38(2):134-43. doi: 10.1111/apt.12352. Epub 2013 May 29.

13.

Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients.

Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R; NASH CRN.

Hepatology. 2013 Nov;58(5):1644-54. doi: 10.1002/hep.26465. Epub 2013 Oct 2.

14.

Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.

Nelson JE, Brunt EM, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network.

Hepatology. 2012 Nov;56(5):1730-40. doi: 10.1002/hep.25856. Epub 2012 Sep 20.

15.

Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.

Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM, McCullough AJ, Bass NM, Diehl AM, Unalp-Arida A, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network.

Hepatology. 2012 Oct;56(4):1311-8. doi: 10.1002/hep.25805. Epub 2012 Aug 21.

16.

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network.

Hepatology. 2012 Sep;56(3):943-51. doi: 10.1002/hep.25772. Epub 2012 Jul 26.

17.

Association between puberty and features of nonalcoholic fatty liver disease.

Suzuki A, Abdelmalek MF, Schwimmer JB, Lavine JE, Scheimann AO, Unalp-Arida A, Yates KP, Sanyal AJ, Guy CD, Diehl AM; Nonalcoholic Steatohepatitis Clinical Research Network.

Clin Gastroenterol Hepatol. 2012 Jul;10(7):786-94. doi: 10.1016/j.cgh.2012.01.020. Epub 2012 Feb 14.

18.

Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A, Diehl AM; NASH CRN.

Hepatology. 2012 Jun;55(6):1711-21. doi: 10.1002/hep.25559. Epub 2012 Apr 18.

19.

Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.

Vos MB, Colvin R, Belt P, Molleston JP, Murray KF, Rosenthal P, Schwimmer JB, Tonascia J, Unalp A, Lavine JE; NASH CRN Research Group.

J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):90-6. doi: 10.1097/MPG.0b013e318229da1a.

20.

Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease.

Guy CD, Suzuki A, Burchette JL, Brunt EM, Abdelmalek MF, Cardona D, McCall SJ, Ünalp A, Belt P, Ferrell LD, Diehl AM; Nonalcoholic Steatohepatitis Clinical Research Network.

Hum Pathol. 2012 Jun;43(6):790-800. doi: 10.1016/j.humpath.2011.07.007. Epub 2011 Oct 28.

Supplemental Content

Loading ...
Support Center